SunTrust Robinson Reiterates a “Buy” Rating on BWX Technologies (BWXT) and $70.0 Target; Iguana Healthcare Management Lowered Its Alexion Pharmaceuticals (ALXN) Position

Among 10 analysts covering BWX Technologies (NYSE:BWXT), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. BWX Technologies has $72 highest and $32 lowest target. $62.33’s average target is -2.55% below currents $63.96 stock price. BWX Technologies had 16 analyst reports since October 13, 2015 according to SRatingsIntel. SunTrust maintained BWX Technologies, Inc. (NYSE:BWXT) on Monday, January 8 with “Buy” rating. Bank of America maintained BWX Technologies, Inc. (NYSE:BWXT) rating on Thursday, October 5. Bank of America has “Buy” rating and $65 target. The firm has “Buy” rating given on Friday, January 19 by SunTrust. The company was reinitiated on Tuesday, October 13 by KeyBanc Capital Markets. The rating was downgraded by Bank of America to “Neutral” on Friday, November 18. The company was initiated on Friday, March 18 by Sidoti. The rating was initiated by Suntrust Robinson on Thursday, January 19 with “Buy”. On Wednesday, November 8 the stock rating was maintained by Robert W. Baird with “Buy”. The rating was maintained by Bank of America on Thursday, August 10 with “Buy”. As per Tuesday, March 21, the company rating was upgraded by Bank of America.

Iguana Healthcare Management Llc decreased Alexion Pharmaceuticals Inc (ALXN) stake by 33.33% reported in 2017Q3 SEC filing. Iguana Healthcare Management Llc sold 20,000 shares as Alexion Pharmaceuticals Inc (ALXN)’s stock declined 11.63%. The Iguana Healthcare Management Llc holds 40,000 shares with $5.61 million value, down from 60,000 last quarter. Alexion Pharmaceuticals Inc now has $27.04B valuation. The stock increased 0.58% or $0.7 during the last trading session, reaching $121.05. About 1.80M shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since January 21, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

Among 28 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 23 have Buy rating, 0 Sell and 5 Hold. Therefore 82% are positive. Alexion Pharmaceuticals Inc. has $257 highest and $82 lowest target. $168.67’s average target is 39.34% above currents $121.05 stock price. Alexion Pharmaceuticals Inc. had 90 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Outperform” rating by BMO Capital Markets on Friday, April 29. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Outperform” rating given on Friday, February 17 by RBC Capital Markets. Robert W. Baird upgraded the stock to “Outperform” rating in Monday, December 18 report. UBS maintained the stock with “Buy” rating in Thursday, February 4 report. As per Monday, September 25, the company rating was maintained by Leerink Swann. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Buy” rating given on Thursday, July 27 by Stifel Nicolaus. The stock has “Buy” rating by Oppenheimer on Thursday, July 27. On Tuesday, September 12 the stock rating was maintained by Robert W. Baird with “Hold”. The firm earned “Buy” rating on Monday, October 23 by SunTrust. The firm earned “Hold” rating on Wednesday, June 14 by Oppenheimer.

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on February, 15. They expect $1.08 earnings per share, down 1.82% or $0.02 from last year’s $1.1 per share. ALXN’s profit will be $241.28M for 28.02 P/E if the $1.08 EPS becomes a reality. After $1.28 actual earnings per share reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -15.63% negative EPS growth.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.20, from 1.37 in 2017Q2. It dived, as 36 investors sold ALXN shares while 174 reduced holdings. 78 funds opened positions while 167 raised stakes. 206.89 million shares or 0.54% less from 208.01 million shares in 2017Q2 were reported. Atria Investments Lc has invested 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Polar Capital Llp has 533,000 shares. Moreover, Atlantic Gp Ltd Liability has 0.01% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 11,329 shares. Magnetar Fincl Lc invested in 0.01% or 3,584 shares. Oakbrook Investments Lc has invested 0.15% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). 46,962 were reported by Piedmont Invest Advsrs Limited Com. Edgewood Mngmt Ltd Liability Corporation accumulated 5,094 shares or 0% of the stock. Kentucky Retirement reported 0.15% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Rockefeller Financial Serv has invested 0.02% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Cwm Ltd Co holds 0% or 136 shares in its portfolio. National Pension Ser has 0.16% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 204,795 shares. Bogle Investment Mngmt LP De reported 0.63% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Sumitomo Mitsui Asset Management Limited holds 0.04% or 17,322 shares. Pictet Cie (Europe) Sa invested 0.14% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Wms Prtnrs Ltd Liability holds 0.04% or 2,105 shares in its portfolio.

Iguana Healthcare Management Llc increased Glaukos Corp stake by 40,000 shares to 100,000 valued at $3.30 million in 2017Q3. It also upped Tesaro Inc (NASDAQ:TSRO) stake by 10,000 shares and now owns 25,000 shares. Adma Biologics Inc (NASDAQ:ADMA) was raised too.

Since July 31, 2017, it had 0 buys, and 6 insider sales for $2.74 million activity. $310,521 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares were sold by HANTSON LUDWIG. On Monday, August 28 O’Neill Julie sold $1.56 million worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 11,160 shares. $96,418 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares were sold by Veneman Ann M. The insider Wagner Heidi L sold $16,800.

The stock increased 0.95% or $0.6 during the last trading session, reaching $63.96. About 286,217 shares traded. BWX Technologies, Inc. (NYSE:BWXT) has risen 41.41% since January 21, 2017 and is uptrending. It has outperformed by 24.71% the S&P500.